
    
      Number of treatment-emergent Adverse Events (AEs) will be reported in Adverse Events section.

      Study was originally designed with both Phase I and Phase II part, but sponsor decided not to
      conduct Phase 2 part due to strategic portfolio re-prioritization.
    
  